For the Inventor, By the Inventor

Enter inventor name

Brussels, Belgium

Hamid R Hoveyda

USPTO Granted Patents = 51 (Patent Applications = 11)

CIPO Patents = 8 (Patent Applications = 1)

EPO Patents = 13 (Patent Applications = 12)

Average Co-Inventor Count = 3.6

ph-index = 11

Forward Citations = 261(Granted Patents)

Forward Citations (Not Self Cited) = 152(Dec 10, 2025)

Location History:

Sherbrooke, CA (2008 - 2011)
Québec, CA (2009 - 2013)
Brussels, BE (2009 - 2023)

Company Filing History:

Tranzyme Pharma Inc.

Ocera Therapeutics, Inc.

Epics Therapeutics

Euroscreen S.a.

Years Active: 2008-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

NK-3 Receptor Antagonists

G-Protein Coupled Receptor Agonists

Chiral Synthesis

Macrocyclic Compounds

Pharmaceutical Composition

Therapeutic Treatments

Leptin-Related Disease

Excess Body Fat

Spatially-Defined Macrocycles

Inflammatory Diseases

Ghrelin Receptor Modulators

Triazolo-Pyrazines

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12458641 - NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat (2025-11-04),

2. 12162849 - Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-deuterated form thereof (2024-12-10),

3. 11731974 - N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists (2023-08-22),

4. 11478472 - NK-3 receptor antagonists for therapeutic treatment of leptin-related disease (2022-10-25),

5. 11078203 - Deuterated fezolinetant (2021-08-03),

6. 11072582 - Substituted pyrrolidines as G-protein coupled receptor 43 agonists (2021-07-27),

7. 10941151 - Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof (2021-03-09),

8. 10836768 - N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists (2020-11-17),

9. 10787458 - Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines (2020-09-29),

10. 10781171 - Substituted pyrrolidines as G-protein coupled receptor 43 agonists (2020-09-22),

11. 10683295 - Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof (2020-06-16),

12. 10624890 - NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat (2020-04-21),

13. 10577318 - Substituted pyrrolidines as G-protein coupled receptor 43 agonists (2020-03-03),

14. 10544150 - NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders (2020-01-28),

15. 10358416 - Substituted pyrrolidines as G-protein coupled receptor 43 agonists (2019-07-23),

Title: The Innovative Work of Hamid R Hoveyda in Brussels, BE

Introduction:

Hamid R Hoveyda is a prolific inventor based in Brussels, BE, with an impressive track record in the field of patents. With a total of 49 patents to his name, Hoveyda is known for his groundbreaking discoveries in the realm of pharmaceuticals and medical treatments.

Latest Patents:

Among his latest patents is the development of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists. This innovation offers a method for treating and/or preventing polycystic ovary syndrome (PCOS) by administering a specific compound. Additionally, Hoveyda has patented the use of NK-3 receptor antagonists for the therapeutic treatment of leptin-related diseases.

Career Highlights:

Hoveyda has made significant contributions to the field through his work with Ogeda Sa and Tranzyme Pharma Inc. His expertise and dedication have led to the development of groundbreaking pharmaceutical solutions that have the potential to make a profound impact on global health.

Collaborations:

Throughout his career, Hoveyda has collaborated with esteemed professionals such as Graeme Lovat Fraser and Mark L Peterson. These collaborations have fostered a culture of innovation and excellence, leading to the successful execution of pioneering research projects.

Conclusion:

In conclusion, Hamid R Hoveyda stands as a pioneering inventor whose relentless dedication to innovation has resulted in numerous impactful patents. His inventive spirit and collaborative approach underscore his commitment to advancing pharmaceutical science for the betterment of society.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…